CLOs on the Move


 
Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.chimaerix.com
  • 2505 Meridian Pkwy Ste 340
    Durham, NC USA 27713
  • Phone: 919. 806.1074

Executives

Name Title Contact Details

Similar Companies

ABcann Global

Our group of companies will be the first to produce repeatable, standardized, plant-based medicines worldwide. ABcann will produce products with integrity in a customer focused culture where social responsibility and environmental impacts are mandated.

ERT

ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.

miraDry

Make excessive sweat a thing of the past. Learn how miraDry® can permanently reduce underarm sweat in as little as one non-surgical treatment.

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.